Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04574635 · ClinicalTrials.gov registry record
Human Papilloma Virus (HPV) Circulating Tumor DNA (ctDNA) in Cervical Cancer
A clinical trial of Cervical Adenosquamous Carcinoma and Recurrent Cervical Carcinoma, sponsored by Mayo Clinic.
- Active
- Registry status
- 18
- Enrollment target
- 2
- Study locations
NCT04574635: Active study of Cervical Adenosquamous Carcinoma and Recurrent Cervical Carcinoma, sponsored by Mayo Clinic.
NCT04574635 is a study of Cervical Adenosquamous Carcinoma and Recurrent Cervical Carcinoma that is active but no longer recruiting, run by Mayo Clinic. The registered enrollment target is 18 participants, below the 113-participant average among 13 other Cervical Adenosquamous Carcinoma trials with a reported enrollment target (84% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04574635, a study of Cervical Adenosquamous Carcinoma and Recurrent Cervical Carcinoma, is active but no longer recruiting, sponsored by Mayo Clinic.
- ACTIVE NOT RECRUITING
- Registry status
- 18 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study collects blood samples to determine if the DNA of HPV that causes cervical cancer can be detected in patients with cervical cancer that is new (primary), has come back (recurrent), or has spread to other places in the body (metastatic) and are undergoing treatment with surgery, radiotherapy, chemotherapy, and/or immunotherapy. Researchers may use this information to predict response (good or bad) of the cervical cancer to treatment and detect recurrent cancer sooner.
Primary Outcome
The proportion will be reported along with the exact 95% binomial confidence interval. Additionally will report the mean standard deviation and median interquartile range ctDNA post-treatment in these patients.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
Study Locations (2)
Minnesota
- University of Minnesota - Minneapolis
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2020-11-17 |
| Est. Completion | 2027-11-30 |
What the registry record for NCT04574635 still lists
NCT04574635 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 113-participant average among 13 other Cervical Adenosquamous Carcinoma trials with a reported enrollment target (84% lower).
The record links to 10 conditions, with Cervical Adenosquamous Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Biospecimen Collection is the first listed.
NCT04574635 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT04574635 about?
NCT04574635 is a clinical study titled "Human Papilloma Virus (HPV) Circulating Tumor DNA (ctDNA) in Cervical Cancer". This study collects blood samples to determine if the DNA of HPV that causes cervical cancer can be detected in patients with cervical cancer that is new (primary), has come back (recurrent), or has spread to other places in the body (metastatic) and are undergoing treatment with surgery, radiothera...
What is the current status of trial NCT04574635?
This trial is currently active not recruiting. The enrollment target is 18 participants. The study started on 2020-11-17. Estimated completion is 2027-11-30.
What conditions does trial NCT04574635 study?
This clinical trial studies the following conditions: Cervical Adenosquamous Carcinoma, Recurrent Cervical Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Metastatic Cervical Carcinoma, Stage IB Cervical Cancer FIGO 2018.
What interventions are being tested in trial NCT04574635?
The interventions under investigation include: Biospecimen Collection (PROCEDURE).
Who is sponsoring clinical trial NCT04574635?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04574635 being conducted?
This trial has 2 study locations across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cervical Adenosquamous Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04574635's enrollment target sits among peer trials
18 13th of 13 higher than 1 of 13 other Cervical Adenosquamous Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cervical Adenosquamous Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors
RECRUITING · Phase 1
-
External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer
RECRUITING · Phase 1
-
Yoga Therapy During Chemotherapy and Radiation Treatment for the Improvement of Physical and Emotional Well-Being in Patients With Stage IB2-IIIB Cervical Cancer
ACTIVE NOT RECRUITING · NA
-
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers
ACTIVE NOT RECRUITING · Phase 3
-
Studying the Physical Function and Quality of Life Before and After Surgery in Patients With Stage I Cervical Cancer
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI